Increased risk weighs on KYOWA KIRIN, penalising its rating down to Neutral
The independent financial analyst theScreener just lowered the general evaluation of KYOWA KIRIN (JP), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as moderately risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Neutral. As of the analysis date January 28, 2022, the closing price was JPY 2,865.00 and its target price was estimated at JPY 2,716.72.Kyowa Hakko Kirin is a pharmaceutical company mainly engaged in medical product and biochemical businesses. Co. operates in two business segments: medical product, and biochemical. Co. is engaged in the manufacture, sale and sales promotion of medical products for hospital use, the development of candidate substances for new drugs, the provision of technologies for antibody drug creation; the manufacture and sale of medical and industrial materials, mainly amino and nucleic acids, and health care products; the design and construction of facilities; the distribution, insurance agency and wholesale businesses.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.